1. Home
  2. KURA
  3. KURA News

Latest Kura Oncology Inc. (KURA) News on September 17, 2025

KURA

MT Newswires

8 days ago

Kura Oncology Insider Bought Shares Worth $410,145, According to a Recent SEC Filing

LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA)
KURA

Insider Monkey

10 days ago

LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA)

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

12 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is the Options Market Predicting a Spike in Kura Oncology Stock?
KURA

Zacks

3 months ago

Is the Options Market Predicting a Spike in Kura Oncology Stock?

KURA

MT Newswires

3 months ago

Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
KURA

GlobeNewswire

3 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

KURA Stock Rises More Than 15% This Past Week: Here's Why
KURA

Zacks

3 months ago

KURA Stock Rises More Than 15% This Past Week: Here's Why

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

3 months ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
KURA

GlobeNewswire

3 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

KURA

MT Newswires

4 months ago

Kura Oncology, Kyowa Get FDA Acceptance, Priority Review of New Drug Application for Ziftomenib

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
KURA

GlobeNewswire

4 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025
KURA

Insider Monkey

4 months ago

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
KURA

GlobeNewswire

4 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

Kura Oncology to Participate in Three Upcoming Investor Conferences
KURA

GlobeNewswire

4 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
KURA

GlobeNewswire

4 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference
KURA

GlobeNewswire

4 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

KURA

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Kura Oncology Inc Earnings Call

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

5 months ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs
KURA

GuruFocus.com

5 months ago

Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
KURA

Zacks

5 months ago

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

KURA

Associated Press Finance

5 months ago

Kura Oncology: Q1 Earnings Snapshot

Kura Oncology Reports First Quarter 2025 Financial Results
KURA

GlobeNewswire

5 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Kura doses first subjects in trial of ziftomenib for advanced GIST
KURA

Clinical Trials Arena

5 months ago

Kura doses first subjects in trial of ziftomenib for advanced GIST

KURA

MT Newswires

5 months ago

Kura Reports Dosing in Phase 1 Ziftomenib Combination Trial

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
KURA

GlobeNewswire

5 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Kura Oncology to Report First Quarter 2025 Financial Results
KURA

GlobeNewswire

5 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

KURA

MT Newswires

5 months ago

Kura Oncology Submits Ziftomenib NDA to FDA for Treating Acute Myeloid Leukemia

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
KURA

GlobeNewswire

5 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

5 months ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Participate in Stifel Targeted Oncology Forum
KURA

GlobeNewswire

6 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
KURA

GlobeNewswire

6 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

6 months ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURA

MT Newswires

6 months ago

UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating

Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago
KURA

Simply Wall St.

7 months ago

Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago

KURA

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Kura Oncology Inc Earnings Call

Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth
KURA

GuruFocus.com

7 months ago

Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth

Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
KURA

Zacks

7 months ago

Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

KURA

Associated Press Finance

7 months ago

Kura Oncology: Q4 Earnings Snapshot

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
KURA

GlobeNewswire

7 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Kura Oncology to Participate in Three Upcoming Investor Conferences
KURA

GlobeNewswire

7 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
KURA

GlobeNewswire

7 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

7 months ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURA

MT Newswires

7 months ago

Wedbush Adjusts Kura Oncology's Price Target to $26 From $34, Maintains Outperform Rating

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
KURA

GlobeNewswire

7 months ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

KURA

MT Newswires

8 months ago

Kura Oncology Promotes Mollie Leoni to Chief Medical Officer

Kura Oncology Announces Senior Executive Promotions
KURA

GlobeNewswire

8 months ago

Kura Oncology Announces Senior Executive Promotions

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
KURA

GlobeNewswire

9 months ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
KURA

Insider Monkey

9 months ago

Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Kura Oncology to Host Virtual Investor Event on December 9, 2024
KURA

GlobeNewswire

10 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
KURA

GlobeNewswire

10 months ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds
KURA

Insider Monkey

10 months ago

Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds

Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
KURA

BioPharma Dive

10 months ago

Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover
KURA

Investor's Business Daily

10 months ago

Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover

Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
KURA

Investor's Business Daily

10 months ago

Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%

KURA

MT Newswires

10 months ago

Wedbush Lowers Price Target on Kura Oncology to $34 From $37, Keeps Outperform Rating

Kura Oncology partners Kyowa Kirin to advance AML treatment
KURA

Pharmaceutical Technology

10 months ago

Kura Oncology partners Kyowa Kirin to advance AML treatment

KURA

MT Newswires

10 months ago

Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
KURA

PR Newswire

10 months ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
KURA

GuruFocus.com

10 months ago

Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses

KURA

Associated Press Finance

10 months ago

Kura Oncology: Q3 Earnings Snapshot

Kura Oncology Reports Third Quarter 2024 Financial Results
KURA

GlobeNewswire

10 months ago

Kura Oncology Reports Third Quarter 2024 Financial Results

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
KURA

GlobeNewswire

10 months ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Kura Oncology to Report Third Quarter 2024 Financial Results
KURA

GlobeNewswire

a year ago

Kura Oncology to Report Third Quarter 2024 Financial Results

KURA

MT Newswires

a year ago

UBS Initiates Kura Oncology With Buy Rating, $27 Price Target

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
KURA

GlobeNewswire

a year ago

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs
KURA

GuruFocus.com

a year ago

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs

KURA

MT Newswires

a year ago

Kura Oncology Reports 'Encouraging' Results From Trial of Potential Leukemia Treatment

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
KURA

GlobeNewswire

a year ago

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
KURA

GlobeNewswire

a year ago

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Kura Oncology to Participate in Cantor Global Healthcare Conference
KURA

GlobeNewswire

a year ago

Kura Oncology to Participate in Cantor Global Healthcare Conference

Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now
KURA

Insider Monkey

a year ago

Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now

KURA

Associated Press Finance

a year ago

Kura Oncology: Q2 Earnings Snapshot

Kura Oncology Reports Second Quarter 2024 Financial Results
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Second Quarter 2024 Financial Results

KURA

MT Newswires

a year ago

Kura Oncology Says FDA Clears Ziftomenib Clinical Study in Advanced GIST

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
KURA

GlobeNewswire

a year ago

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

Kura Oncology to Report Second Quarter 2024 Financial Results
KURA

GlobeNewswire

a year ago

Kura Oncology to Report Second Quarter 2024 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
KURA

Simply Wall St.

a year ago

Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Participate in Jefferies Global Healthcare Conference
KURA

GlobeNewswire

a year ago

Kura Oncology to Participate in Jefferies Global Healthcare Conference

KURA

MT Newswires

a year ago

Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
KURA

GlobeNewswire

a year ago

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

2 Incredible Growth Stocks to Buy Hand Over Fist
KURA

Motley Fool

a year ago

2 Incredible Growth Stocks to Buy Hand Over Fist

Kura Oncology to Participate in Bank of America Securities Healthcare Conference
KURA

GlobeNewswire

a year ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
KURA

Insider Monkey

a year ago

Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURA

GuruFocus.com

a year ago

Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ...

KURA

Associated Press Finance

a year ago

Kura Oncology: Q1 Earnings Snapshot

Kura Oncology Reports First Quarter 2024 Financial Results
KURA

GlobeNewswire

a year ago

Kura Oncology Reports First Quarter 2024 Financial Results

Kura Oncology to Report First Quarter 2024 Financial Results
KURA

GlobeNewswire

a year ago

Kura Oncology to Report First Quarter 2024 Financial Results

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
KURA

GlobeNewswire

a year ago

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology to Participate in Stifel Targeted Oncology Forum
KURA

GlobeNewswire

a year ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

a year ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
KURA

GlobeNewswire

2 years ago

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA

GlobeNewswire

2 years ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript
KURA

Insider Monkey

2 years ago

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript

KURA

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Kura Oncology Inc Earnings Call

KURA

GuruFocus.com

2 years ago

Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results

Share on Social Networks: